Lparomlimab and Tuvonralimab is named as an intervention in 2 current clinical trials in our China register. 1 is recruiting patients now. All registered phases are Phase 2. The lead sponsor is Tianjin Medical University Cancer Institute and Hospital. The most-studied condition is HCC.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma
NCT07099274 · ClinicalTrials.gov ↗ · HCC
|
Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | China |
|
Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer
NCT07379398 · ClinicalTrials.gov ↗ · NSCLC
|
Phase 2 | Not yet open | Tianjin Medical University Cancer Institute and Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Tianjin Medical University Cancer Institute and Hospital | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name Lparomlimab and Tuvonralimab as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Tianjin Medical University Cancer Institute and Hospital. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Lparomlimab and Tuvonralimab works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Lparomlimab and Tuvonralimab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Lparomlimab and Tuvonralimab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.